Abivax ADR (NASDAQ:ABVX) has a beta value of 0.25 and has seen 1.08 million shares traded in the recent trading session. The company, currently valued at $599.81M, closed the recent trade at $9.45 per share which meant it gained $0.6 on the day or 6.78% during that session. The ABVX stock price is -49.84% off its 52-week high price of $14.16 and 49.52% above the 52-week low of $4.77. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.5 million shares traded. The 3-month trading volume is 254.21K shares.
The consensus among analysts is that Abivax ADR (ABVX) is Buy stock at the moment, with a recommendation rating of 1.15. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight.
Abivax ADR (NASDAQ:ABVX) trade information
Sporting 6.78% in the green today, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the ABVX stock price touched $9.45 or saw a rise of 5.69%. Year-to-date, Abivax ADR shares have moved -30.67%, while the 5-day performance has seen it change 13.72%. Over the past 30 days, the shares of Abivax ADR (NASDAQ:ABVX) have changed 35.39%. Short interest in the company has seen 1.26 million shares shorted with days to cover at 4.83.
Wall Street analysts have a consensus price target for the stock at $12, which means that the shares’ value could jump 21.25% from the levels at last check today.. The projected low price target is $12.0 while the price target rests at a high of $12.0. In that case, then, we find that the latest price level in today’s session is -26.98% off the targeted high while a plunge would see the stock gain -26.98% from the levels at last check today..
Abivax ADR (ABVX) estimates and forecasts
The company’s shares have gained 45.39% over the past 6 months.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -1.44% over the past 5 years. Earnings growth for 2025 is a modest 3.78% while over the next 5 years, the company’s earnings are expected to increase by 9.83%.
ABVX Dividends
Abivax ADR is expected to release its next earnings report on 2025-Mar-24 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Abivax ADR (NASDAQ:ABVX)’s Major holders
Investors are also buoyed by the number of investors in a company, with Abivax ADR having a total of 49.0 institutions that hold shares in the company. The top two institutional holders are TCG CROSSOVER MANAGEMENT, LLC with over 6.06 million shares worth more than $80.07 million. As of 2024-06-30, TCG CROSSOVER MANAGEMENT, LLC held 14.0635% of shares outstanding.
The other major institutional holder is DEEP TRACK CAPITAL, LP, with the holding of over 4.18 million shares as of 2024-06-30. The firm’s total holdings are worth over $55.26 million and represent 9.7055% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are abrdn World Healthcare Fund and Franklin Strategic Series-FRANKLIN BIOTECHNOLOGY DISCOVERY FUND . As of Mar 31, 2025 , the former fund manager holds about 1.12% shares in the company for having 710.52 shares of worth $6.81 million while later fund manager owns 497.69 shares of worth $4.77 million as of Apr 30, 2025 , which makes it owner of about 0.78% of company’s outstanding stock.
